Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi is conducting a Phase 2a clinical study titled ‘A 52-week ...

Anti-tumor necrosis factor (TNF) therapy for new-onset inflammatory bowel disease (IBD) was independently associated with progressive kidney function decline but not survival, a VA cohort study ...

Tumor necrosis factor inhibitor use was independently associated with a greater risk for progressive kidney function decline but not risk for all-cause mortality among patients with new-onset ...

INmune Bio is developing immunotherapies for cancer and Alzheimer’s, focusing on TNF and NK cell platforms. Their lead drug candidate, XPro, is in Phase 2 trials for early Alzheimer’s disease ...

Treating psoriatic arthritis (PsA) patients with more than one targeted therapy appears to be just fine, with no increased ...